Faeth Therapeutics (FTH) Enterprise Value (2021 - 2026)

Faeth Therapeutics (FTH) has reported Enterprise Value for 6 consecutive years, with -$38.6 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Enterprise Value fell 116.74% year-over-year to -$38.6 million; the trailing twelve-month figure through Jun 2026 stood at -$38.6 million (down 116.74% YoY), and the FY2025 full-year result was -$7.7 million, down 103.76% from the prior year.
• Enterprise Value retreated to -$38.6 million in Q2 2026 per FTH's latest filing, from $167.9 million in the prior quarter.
• Across five years, Enterprise Value topped out at $1.3 billion in Q1 2022 and bottomed at -$38.6 million in Q2 2026.
• Historically, Enterprise Value has averaged $422.7 million across 5 years, with a median of $270.0 million in 2023.
• The widest YoY moves for Enterprise Value: up 2.2% in 2026, down 116.74% in 2026.
• Over 5 years, Enterprise Value stood at $809.7 million in 2022, then plunged by 65.34% to $280.7 million in 2023, then slipped by 26.8% to $205.4 million in 2024, then slumped by 103.76% to -$7.7 million in 2025, then sank by 399.8% to -$38.6 million in 2026.
• According to Business Quant data, Enterprise Value over the past three periods registered -$38.6 million, $167.9 million, and -$7.7 million for Q2 2026, Q1 2026, and Q4 2025 respectively.